Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for Revelumide tablets and will conduct clinical trials in the near future.

Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for Revelumide tablets and will conduct clinical trials in the near future.